Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Consensus Target Price of $9.60 According to Analysts

Shares of Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $9.60.

Several research analysts recently commented on the stock. Guggenheim started coverage on shares of Entera Bio in a research note on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, October 15th. UBS Group set a $9.00 price objective on shares of Entera Bio in a research report on Friday, September 18th. Cantor Fitzgerald started coverage on shares of Entera Bio in a research note on Tuesday, September 22nd. They issued an “overweight” rating on the stock. Finally, Wall Street Zen lowered shares of Entera Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th.

Read Our Latest Report on ENTX

Entera Bio Price Performance

ENTX stock opened at $3.11 on Friday. The business’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $1.99. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20. The firm has a market cap of $541.58 million, a price-to-earnings ratio of -7.97 and a beta of 1.48.

Entera Bio (NASDAQ:ENTX – Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Research analysts expect that Entera Bio will post -0.40 EPS for the current year.

Institutional Trading of Entera Bio

A number of large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP lifted its holdings in shares of Entera Bio by 51.9% in the 1st quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after buying an additional 70,224 shares during the period. Marshall Wace LLP bought a new position in shares of Entera Bio during the 3rd quarter worth $613,000. Renaissance Technologies LLC grew its position in shares of Entera Bio by 338.4% during the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock worth $526,000 after buying an additional 365,441 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in shares of Entera Bio during the third quarter valued at $8,744,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

Further Reading

Analyst Recommendations for Entera Bio (NASDAQ:ENTX)

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.